Wednesday, 21 August 2019

Glenmark to commercialise Ryaltris in Australia, NZ

06 July 2018 | News

Glenmark will receive an upfront payment as well as regulatory and commercial milestone payments from Seqirus.

Image credit- zeebiz.com

Image credit- zeebiz.com

Glenmark Pharma’s subsidiary Glenmark Specialty has entered into an exclusive licensing agreement with Australia's Seqirus to commercialise its nasal spray Ryaltris in Australia and New Zealand.

Ryaltris is indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.

Under the terms of the agreement, Glenmark will be responsible for product supply and Seqirus will be responsible for regulatory filing and commercialisation of the product in Australia and New Zealand.

Glenmark will receive an upfront payment as well as regulatory and commercial milestone payments from Seqirus.

In May 2018, Glenmark filed a New Drug Application (NDA) for Ryaltris with the US Food and Drug Administration (USFDA).

The company plans to commercialise Ryaltris in several key markets globally.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Will APAC lead the way for innovation in the field of precision medicine?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls